Epigenic Therapeutics

Focus: Epigenic Therapeutics is a Shanghai-based gene editing therapy company founded in 2024, currently in Series A stage with no publicly disclosed revenue or commercial products.

Gene Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Epigenic Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Epigenic Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

EPI-003

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT06661148Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients

Phase 1

Help build intelligence for Epigenic Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Ground-floor opportunity at an early-stage gene editing company with potential to build core capabilities in an expanding therapeutic modality
Shanghai headquarters positions you in a rapidly growing biotech ecosystem with access to Asian market development and regulatory pathways
Series A stage allows meaningful career growth as the company scales from pre-clinical/early-clinical phase toward clinic readout

Watch Out For

Company is less than 1 year old with no disclosed clinical trials, approved products, or revenue—execution risk is high and runway uncertain
No active job openings currently listed, and missing critical data (employee count, funding amount, H1B sponsorship history) suggest limited transparency or early hiring phase

Generated by Claude from Epigenic Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

EPI-003

Chronic Hepatitis B

Phase 1

Clinical Trials (1)

NCT06745973An Exploratory Clinical Study Evaluating EPI-003 Injection for the Treatment of Chronic Hepatitis B

Phase 1

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2024

Portfolio: 2 clinical trials

Top TAs: Infectious Diseases

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Infectious Diseases

2 pipeline

Marketed

Pipeline